CONCORD – With some elective surgeries now being cancelled and delayed in New Hampshire due to a national shortage of ...

Dr. Marla Lipsyc-Sharf reviews her recent session at the 2024 SABCS meeting, discussing biopsy approaches and treatment ...

PDC*line Pharma, a clinical-stage biotech company developing a new class of immunotherapies for cancers, presented the ...

Osmotic Pumps Market. The global osmotic pumps market is set for substantial growth, with revenue projected to rise from USD ...

Roche presents new and updated data for fixed-duration Columvi and Lunsumio at ASH 2024 meeting: Basel Wednesday, December 11, 2024, 11:00 Hrs [IST] Roche announced that new and u ...

"Medical Journeys" chart a path each step of the way for physicians and patients and provide continual resources and support, ...

After recently taking steps to undo messaging about a rival product in the European Union, CSL Vifor is carrying its amends ...

While 88.1% of patients completed one cycle, patient adherence beyond the fourth cycle was relatively low.

New data from three oral presentations, which demonstrated significant clinical benefit with Sarclisa-based quadruplets in newly diagnosed multiple myeloma (NDMM) patients were featured at the 66th ...

Elizabeth A. Brem, MD, an assistant clinical professor in the Division of Hematology/Oncology, School of Medicine at the University of California, Irvine, discusses multiple types of therapies used in ...

Attorney General Kris Mayes took the first steps Friday to putting convicted murderer Aaron Gunches to death. Mayes asked the ...